Welcome to Merz North America

Merz North America is a specialty healthcare company dedicated to the development and marketing of innovative quality products for physicians and patients across the US. Our products are distributed through two divisions: Aesthetics and Neurosciences.

News

Merz Named “Top Aesthetics Company” by Aesthetic Everything® for Third Year in a Row

Merz Named “Top Aesthetics Company” by Aesthetic Everything® for Third Year in a Row... Merz Americas CEO Bob Rhatigan named “Top Aesthetics CEO” for the third year in a row.... Key products XEOMIN®(incobotulinumtoxinA) and Ultherapy® recognized with best-in-class awards

Read More

Merz to Present Data Across Aesthetics Portfolio at “The Aesthetic Meeting 2019” in New Orleans

Accepted abstracts provide key updates on aesthetics products, including XEOMIN® (incobotulinumtoxinA), ULTHERAPY®, RADIESSE® and CELLFINA®.

Read More

FDA Approves Broadened Indication for XEOMIN® (incobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in Adult Patients

Merz Americas announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN®(incobotulinumtoxinA), broadening its indication to be a first-line treatment of blepharospasm (involuntary blinking) in adult patients.

Read More